

Jes s Rivera-Nieves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6170118/publications.pdf>

Version: 2024-02-01

27
papers

1,294
citations

567281

15
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

2234
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody secreting cells are critically dependent on integrin $\alpha 4 \beta 7$ /MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. <i>Mucosal Immunology</i> , 2022, 15, 109-119.	6.0	15
2	Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. <i>Drugs</i> , 2021, 81, 985-1002.	10.9	89
3	Vitamin D Levels May Predict Response to Vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1978-1979.	1.3	0
4	An integrin $\alpha 4 \beta 7$ -dependent mechanism of IgA transcytosis requires direct plasma cell contact with intestinal epithelium. <i>Mucosal Immunology</i> , 2021, 14, 1347-1357.	6.0	9
5	Microbial-Driven Immunological Memory and Its Potential Role in Microbiome Editing for the Prevention of Colorectal Cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 752304.	3.9	2
6	Class Ib MHC α -Mediated Immune Interactions Play a Critical Role in Maintaining Mucosal Homeostasis in the Mammalian Large Intestine. <i>ImmunoHorizons</i> , 2021, 5, 953-971.	1.8	0
7	$\alpha 4 \beta 7$ Integrin Inhibition Can Increase Intestinal Inflammation by Impairing Homing of CD25 ^{hi} FoxP3 ⁺ Regulatory T Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 369-385.	4.5	22
8	Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 216-228.	1.9	19
9	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097121.	3.2	7
10	Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1364-1377.	1.3	7
11	Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2634-2643.	4.4	85
12	Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. <i>Frontiers in Pharmacology</i> , 2019, 10, 212.	3.5	92
13	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 270-282.	1.9	48
14	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 410-420.	1.9	28
15	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. <i>Frontiers in Immunology</i> , 2018, 9, 2082.	4.8	35
16	Targeting leukocyte traffic: A new era for the treatment of Inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S631-S632.	1.3	1
17	Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2366-2376.	1.9	6
18	Defective Lymphatics in Crohn's Disease: Tertiary Lymphoid Follicles Plug the Gap. <i>Gastroenterology</i> , 2017, 152, 908-910.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Ectopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur?. <i>Frontiers in Immunology</i> , 2016, 7, 308.	4.8	30
20	Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1003-1012.	2.3	17
21	Integrin-based therapeutics: biological basis, clinical use and new drugs. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 173-183.	46.4	324
22	Innate Cytokines Dictate the Fate of Acute Intestinal Inflammation. <i>Gastroenterology</i> , 2015, 148, 248-250.	1.3	6
23	A Call for Investment in Education of US Minorities in the 21st Century. <i>Gastroenterology</i> , 2013, 144, 863-867.	1.3	10
24	Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2013, 14, 1490-1500.	2.1	38
25	Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1315-1325.e4.	4.4	54
26	Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. <i>Gastroenterology</i> , 2005, 128, 654-666.	1.3	150
27	Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. <i>Gastroenterology</i> , 2001, 121, 1428-1436.	1.3	198